Biblio
.
Post-transplant cyclophosphamide at 80 mg/kg with low dose post-engraftment anti-thymocyte globulin in haploidentical transplantation with myeloablative conditioning. Bone Marrow Transplant. 2024.
. Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation. Cancer Chemother Pharmacol. 2019.
. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study. BMC Cancer. 2019;19(1):819.
. Low incidence of relapse with moderate conditioning regimen of fludarabine, busulfan and melphalan for patients with myeloid malignancies: a single-center analysis of 100 patients. Transplant Cell Ther. 2023.
. Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial. J Clin Oncol. 2020:JCO1903277.
A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment. Cell Rep Med. 2023:101286.